Brief: Prosomnus Enrolls First Participant In Study Evaluating Prosomnus Evo™ In Treating Severe Obstructive Sleep Apnea
19/12/2022 13:02
Dec 19 (Reuters) - Prosomnus Inc OSA.O :
* PROSOMNUS® ENROLLS FIRST PARTICIPANT IN STUDY EVALUATING
SAFETY
AND EFFICACY OF PROSOMNUS EVO™ IN TREATING SEVERE OBSTRUCTIVE
SLEEP APNEA
* INTENDS TO USE DATA FROM SOS STUDY TO APPLY FOR AN
EXPANDED
INDICATION FOR USE WITH FDA
Source text for Eikon: ID:nGNX2sKMYl
Further company coverage: OSA.O
((Reuters.Briefs@thomsonreuters.com))
Recent news on ProSomnus
See all newsBrief: Prosomnus Sleep Technologies Says Co Enters Into Voluntary Chapter 11 Restructuring Process Which Will Take Company Private, Reduce Debt
Prosomnus Inc expected to post a loss of 31 cents a share - Earnings Preview
Prosomnus Inc expected to post a loss of 31 cents a share - Earnings Preview
Brief: Prosomnus Raises $10 Million To Fuel Growth And Optimize Operations
Brief: Updated Clinical Trial Data Indicates Precision Oral Appliance Therapy With Prosomnus Devices Is Non-Inferior To Cpap Therapy For The Treatment Of Moderate To Severe Obstructive Sleep Apnea